Letairis (ambrisentan) is used to treat pulmonary arterial hypertension (PAH or high blood pressure in the vessels that carry blood to the lungs). Letairis has been shown to improve the ability to exercise and slow the worsening of symptoms in patients with PAH. Letairis is in a class of medications called endothelin receptor antagonists. These drugs work by stopping the action of endothelin, a natural substance that causes blood vessels to narrow which prevents normal blood flow in people who have PAH.
FDA Drug Safety Communication: Liver injury warning to be removed from Letairis (ambrisentan) tablets
Questions & Answers: Liver injury warning to be removed from Letairis (ambrisentan) tablets
FDA Drug Safety Podcast for Healthcare Professionals: Liver injury warning to be removed from Letairis (ambrisentan) tablets[ARCHIVED]